XY Capital Ltd Buys 55,736 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM

XY Capital Ltd lifted its stake in shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 115.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 104,130 shares of the company’s stock after buying an additional 55,736 shares during the period. HUTCHMED comprises approximately 1.1% of XY Capital Ltd’s investment portfolio, making the stock its 17th biggest position. XY Capital Ltd owned approximately 0.06% of HUTCHMED worth $1,120,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of HCM. Ameriprise Financial Inc. grew its position in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after purchasing an additional 5,538 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of HUTCHMED during the first quarter worth about $365,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after purchasing an additional 4,116 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors.

Trending Headlines about HUTCHMED

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: HUTCHMED granted GSK exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. The deal includes a $110 million upfront payment and could generate up to $1.295 billion in total milestone payments, plus royalties. Reuters article
• Positive Sentiment: The partnership validates HUTCHMED’s oncology pipeline through a major global pharmaceutical partner and could provide funding and development support for HMPL-A830. The drug is expected to enter clinical trials in the second half of 2026. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HCM from “hold” to “buy.” Panmure and Cavendish also reiterated “buy” ratings, citing the GSK deal and what they view as an overlooked valuation relative to HUTCHMED’s expanding oncology pipeline. Broker responses
• Neutral Sentiment: Management discussed the strategic partnership and licensing arrangement in an investor transcript, providing additional details on HMPL-A830’s development and the collaboration with GSK. Seeking Alpha transcript
• Negative Sentiment: HMPL-A830 remains an experimental therapy, so the milestone value is contingent on successful clinical development, regulatory approvals and commercialization. Investors may therefore continue to weigh substantial drug-development risk despite the sizable headline deal.

HUTCHMED Trading Down 0.1%

NASDAQ:HCM opened at $14.09 on Friday. The company has a fifty day moving average of $11.76 and a 200-day moving average of $12.73. The company has a current ratio of 5.64, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06. HUTCHMED has a twelve month low of $9.77 and a twelve month high of $18.30.

HUTCHMED (NASDAQ:HCM) last issued its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.09). The company had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million. On average, analysts predict that HUTCHMED will post 0.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HCM. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Bank of America decreased their price target on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Daiwa Securities Group raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Weiss Ratings lowered shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.87.

HUTCHMED Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.